Karine Tawagi, Assistant Professor of Clinical Medicine and Fellowship Program Director at the University of Illinois Chicago, shared a post on X:
“Great meeting with friends colleagues at MATOS GU26 on the future of GUonc and highlighting irAE colitis management:
- Early ID
- Data for stool lactoferrin/calprotectin
- When SSAs (table below comparing infliximab, vedolizumab, tofacitinib ustekinumab)
- When can resume ICI.”

Other articles featuring Karine Tawagi on OncoDaily.